INBS (Intelligent Bio Solutions) EBIT: $-11.55 Mil (TTM As of Mar. 2026)


INBS Intelligent Bio Solutions Inc INBS
46 GF Score
Price $2.16
GF Value $3.93
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Intelligent Bio Solutions EBIT?

Intelligent Bio Solutions INBS -2.49% 46 EBIT is $-11.55 Mil as of Mar. 2026. GuruFocus rates INBS with a GF Score™ of 46/100 and a GF Value™ of $3.93 (Possible Value Trap). The stock has 3 warning signs investors should review.

Intelligent Bio Solutions's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.87 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Intelligent Bio Solutions's annualized ROC % for the quarter that ended in Mar. 2026 was -125.59%. Intelligent Bio Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -530.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Intelligent Bio Solutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 20,261.40%.

Intelligent Bio Solutions  (NAS:INBS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Intelligent Bio Solutions's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-11.768 * ( 1 - 0% )/( (12.652 + 6.088)/ 2 )
=-11.768/9.37
=-125.59 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17.653 - 4.261 - ( 0.74 - max(0, 5.127 - 12.175+0.74))
=12.652

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.863 - 3.636 - ( 6.862 - max(0, 4.611 - 9.75+6.862))
=6.088

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Intelligent Bio Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.46/( ( (2.209 + max(-3.203, 0)) + (2.114 + max(-1.903, 0)) )/ 2 )
=-11.46/( ( 2.209 + 2.114 )/ 2 )
=-11.46/2.1615
=-530.19 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.457 + 0.59 + 0.481) - (4.261 + 0 + 0.47)
=-3.203

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.878 + 0.597 + 0.844) - (3.636 + 0 + 0.586)
=-1.903

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Intelligent Bio Solutions's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-11.549/-0.057
=20,261.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intelligent Bio Solutions EBIT Related Terms

Intelligent Bio Solutions EBIT Historical Data

* Premium members only.

The historical data trend for Intelligent Bio Solutions's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intelligent Bio Solutions EBIT Chart

Intelligent Bio Solutions Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only -5.97 -8.33 -10.44 -10.02 -10.54

Intelligent Bio Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -3.06 -2.99 -2.63 -2.87

INBS vs RBOT, XAIR, LUDG: EBIT Comparison

For the Medical Devices subindustry, Intelligent Bio Solutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelligent Bio Solutions EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Intelligent Bio Solutions's EV-to-EBIT falls into.


INBS
46GF Score
Intelligent Bio Solutions Inc INBS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intelligent Bio Solutions EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-11.55 Mil mean?
Intelligent Bio Solutions (INBS) has a EBIT of $-11.55 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Intelligent Bio Solutions.
Is Intelligent Bio Solutions' EBIT too high?
Intelligent Bio Solutions' current EBIT is $-11.55 Mil. Overall, Intelligent Bio Solutions has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' EBIT compare to RBOT and XAIR?
Intelligent Bio Solutions' EBIT of $-11.55 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Intelligent Bio Solutions. Intelligent Bio Solutions's current EBIT is $-11.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Possible Value Trap. The stock's GF Value™ is $3.93, compared to a current price of $2.16 — trading 45% below its estimated fair value. The current EBIT is $-11.55 Mil. Intelligent Bio Solutions' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current EBIT is $-11.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intelligent Bio Solutions (INBS) Overvalued in 2026?

Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued. The current stock price of $2.16 is trading 45% below its estimated GF Value™ of $3.93. GuruFocus considers Intelligent Bio Solutions to be Possible Value Trap.

Key valuation signals for INBS:

  • EBIT: $-11.55 Mil
  • GF Value™: $3.93 vs. price of $2.16 (45% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intelligent Bio Solutions Business Description

Address 135 West, 41ST Street, 5th Floor, New York, NY, USA, 10036
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
46GF Score

Get the complete analysis for INBS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$3.93
GF Value